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S U M M A R Y
Objective: To identify clinical predictors of mortality in HIV-2-infected individuals that may be used in
place of CD4 count or plasma viral load (PVL) to guide treatment management in resource-limited
settings.
Methods: A prospective community cohort study of HIV-infected and HIV-negative individuals in a rural
area of Guinea-Bissau has been ongoing since 1989. In 2003 participants were invited for a clinical
examination and blood tests. They were followed-up for vital status until 2010. Antiretroviral treatment
(ART) became available in 2007. Cox regression was used to examine the association of clinical measures
(World Health Organization (WHO) stage, body mass index (BMI), mid-upper arm circumference
(MUAC), and WHO performance scale) measured in 2003 with subsequent mortality.
Results: In 2003, 146 HIV-2-infected individuals (68% women; mean age 56 years) were examined. Over
the next 7 years, 44 (30%) died. BMI < 18.5 kg/m2 was associated with a crude mortality hazard ratio
(HR) of 1.9 (95% conﬁdence interval (CI) 1.0–3.9, p = 0.08); adjusted for age and sex, HR 1.8 (95% CI 0.9–
3.8, p = 0.1). MUAC <230 mm in women and <240 mm in men was also associated with an elevated
mortality HR, though statistical evidence was weak (crude HR 2.2, 95% CI 0.9–5.3, p = 0.1). WHO clinical
stage and WHO performance scale were not associated with mortality (p = 0.6 and p = 0.2, respectively,
for crude associations).
Conclusions: Baseline BMI, MUAC, WHO stage, and WHO performance scale were not strong or
statistically signiﬁcant predictors of mortality among HIV-2-infected individuals. CD4 count and PVL are
more reliable tools, when available, for the management of HIV-2-infected patients in the community
setting.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. 
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Human immunodeﬁciency virus type 2 (HIV-2) is mostly
restricted to West Africa, the highest prevalence having been
observed in Guinea-Bissau.1 The mortality rate of HIV-2-infected
subjects is approximately two times higher than that of HIV-
negative subjects.2–5 This contrasts with an 8-fold increased
mortality rate in HIV-1-infected individuals compared to HIV-
negative individuals.6,7 It is thought that a large proportion of HIV-
2-infected individuals do not progress to AIDS,8,9 or progress more* Corresponding author.
E-mail address: annabelle.gourlay@lshtm.ac.uk (A.J. Gourlay).
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doi:10.1016/j.ijid.2012.01.001slowly than HIV-1-infected individuals.8,10 However HIV-2 can
progress to AIDS with similar clinical features to those in HIV-1-
infected individuals.
In low-income settings, clinical measures may offer practical
criteria for the management of HIV-infected patients and for the
decision to start antiretroviral treatment (ART). CD4 count and
plasma viral load (PVL) predict mortality with HIV-2 infection,2,5,11–
13 but laboratory testing for these markers is often not feasible.
Clinical predictors of mortality with HIV-1 infection, such as
body mass index (BMI)14–17 and World Health Organization
(WHO) clinical stage,18,19 have been documented. Whether they
also predict mortality with HIV-2 infection is less clear, as the few
studies conducted among HIV-2-infected individuals were mostly
hospital-based and limited to patients with more advanced Ltd. Open access under CC BY-NC-ND license.
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further investigate the role of clinical measures in the management
of HIV-2 infection. In this study we explore the utility of clinical
predictors for mortality in HIV-2-infected adults in a community
cohort in Guinea-Bissau.
2. Methods
2.1. Study setting
The study was conducted in the rural area of Caio in north-
western Guinea-Bissau. Caio consists of a string of settlements in
cashew forest, divided into 10 zones. Villagers mostly work as
subsistence farmers. A large number of male villagers leave to
work in Guinea-Bissau’s main commercial centers, or abroad in
Senegal, Portugal, and France. This results in a high ratio of women
to men in the remaining population. A health center is located in
the central zone of Caio.
2.2. Participants
An HIV survey was ﬁrst conducted among adults (aged 15
years) in the community in 1989–1991.21 All HIV-positive
individuals (HIV-1 or HIV-2) identiﬁed plus an equal number of
HIV-negative individuals, frequency-matched on age, gender, and
village zone, were invited to enroll in a cohort. Participants were
invited for a physical examination and blood test in 1991, 1996,
2003, and 2006. Another population serological survey was
conducted in 1997–1998, and newly identiﬁed HIV-positive
individuals and a similar number of HIV-negative individuals
were added to the cohort.22
2.3. 2003 clinical study
All cohort members were invited to participate in the 2003
study round. After obtaining informed consent, a physical
examination was done and medical history and a blood sample
were taken. The ﬁeld workers and physicians were unaware of
participant HIV status. Treatments were prescribed as indicated.
2.4. Follow-up of vital status
Vital status was determined annually in a community-wide
census. People who were temporarily absent were visited up to
three times by ﬁeld workers. If they remained in close contact with
their families, and were expected back, they were considered to be
alive and resident in Caio. For people who had permanently left and
whose whereabouts were unknown by their family, date of leaving
the village (last known to be alive) was recorded and the subject
was considered lost to follow-up. Deaths were considered to be
accurately recorded, even if they occurred abroad, since the
community strictly practises death rituals and family links are very
strong. When an individual dies outside Caio, their body or a
symbolic mat is sent back to the village. Field workers were
unaware of participant HIV status. Census information up to July
2010 was used to determine vital status.
2.5. Laboratory procedures
Laboratory procedures for HIV testing, PVL, and CD4 are
described in Leligdowicz et al.23 In brief, screening for HIV
antibodies was done using ICE HIV 1.2.O (Murex Diagnostics), and
if positive, samples were tested with two monospeciﬁc ELISAs
(Wellcozyme HIV Recombinant I and ICE HIV-2, Abbott Murex).
Indeterminate serology was resolved using nested-PCR.2.6. Ethics and ART
Ethical approval was granted by the London School of Hygiene
and Tropical Medicine Ethics Committee, the Gambia Government/
MRC Laboratories Joint Ethics Committee, and the Research
Committee of the Ministry of Health of Guinea-Bissau.
ART became available in Caio in 2007. From this time,
participants were offered ART if they had undergone pre- and
post-test counseling, had obtained their HIV test results, were HIV-
infected, and were eligible. Co-trimoxazole prophylaxis was
offered to HIV-infected patients aware of their status who had
symptoms or CD4 <28%. All participants received free care from a
physician who was permanently based at the project.
2.7. Statistical methods
All results were double-entered and veriﬁed in Access 2000
(Microsoft, Redwood, WA, USA). Statistical analyses were done
using Stata version 11.1 (StataCorp, College Station, TX, USA).
BMI was calculated by weight (kg) divided by squared height
(m), and grouped into a binary variable based on the suggested
WHO cut-off of 18.5 kg/m2 for malnourished adults.24 Mid-upper
arm circumference (MUAC) was categorized using a cut-off of
230 mm for women and 240 mm for men.24
Based on information from the 2003 clinical examination,
history, and laboratory data, individuals were assigned a WHO
clinical stage (2006 revision25). The staging system and algorithm
are hierarchical: individuals are assigned to the highest stage
(most advanced disease) indicated by their symptoms. Most
conditions were diagnosed clinically as diagnostic facilities were
limited (Appendix A). Physicians also classiﬁed individuals
according to the WHO performance scale, a subjective assessment
of health status, ranging from 1 (asymptomatic) to 4 (symptomatic
and bedridden over 50% of the day).
Differences between groups for categorical variables were
analyzed using the Chi-square test, or Fisher’s exact test; t-tests
were used to compare normally distributed continuous variables
and Wilcoxon rank sum tests for not normally distributed
variables. Person-time was calculated from date of examination
in 2003 to death, or date permanently moved out of the area (no
further information available for the subject), or date ART started,
whichever came ﬁrst. Individuals were classiﬁed according to their
baseline HIV serostatus.
Kaplan–Meier plots were used to explore survival differences
and log-rank tests to compare survival probabilities. Cox regres-
sion was used to obtain hazard ratios (HR) for the effect of HIV
status and other explanatory variables on mortality. To examine
the predictive effect of each clinical measure in its own right on
mortality, crude mortality HRs were calculated, then adjusted a
priori for age and sex. The predictive effects independent of CD4%
and PVL were also explored by further adjusting for these markers.
3. Results
3.1. Participants
Five hundred and forty-seven eligible individuals identiﬁed in
January 2003 from the demographic database were visited in their
homes. Twenty-six (5%) individuals had died, 97 (18%) were not
present, two (0.4%) had permanently moved away, and 15 (3%)
refused to participate. Four hundred and seven were recruited into
the study, of whom ﬁve (1%) declined to be tested; hence 402
individuals were included (Figure 1). Of the 402 participants, 146
(36%) were HIV-2-infected and 197 (49%) were HIV-negative.
There were 29 HIV-1-infected and 30 HIV-1/2 dually-infected
Figure 1. Flow-chart of a community cohort of HIV-infected and HIV-negative individuals in Guinea-Bissau, examined in 2003 and followed-up until 2010.
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because of small numbers.
3.2. Characteristics at baseline
The characteristics of study participants in 2003 are presented
in Table 1. Seventy one percent of participants were female. The
sex distribution of HIV-2-infected subjects was similar to that of
HIV-negative subjects, but they were older (p = 0.01).
Median BMI and mean MUAC observed in HIV-2-infected and
HIV-negative individuals were well above the cut-offs and were
similar in the two groups (BMI p = 0.6, MUAC p = 0.4). Seventeen
percent of HIV-2-infected individuals had BMI <18.5 kg/m2,
compared to 11% of HIV-negative subjects (p = 0.1). An even
smaller proportion of individuals had MUAC below the cut-off: 8%
in HIV-2-infected subjects compared to 5% in HIV-negative
individuals (p = 0.2).
The majority of HIV-2-infected individuals were in WHO
clinical stage 1; the proportions in stage 2 and stage 3/4 were
higher than those in HIV-negative individuals (p = 0.05). WHO
clinical stage was associated with CD4% (p = 0.004). HIV-2-infected
and HIV-negative individuals had similar distributions according
to the WHO performance scale (p = 0.4).
HIV-2-infected individuals had a median PVL of 1124 copies/ml
(interquartile range (IQR) 50–6792) and a median CD4 of 31% (IQR
26–38%). Only 4% were in the lowest CD4% category (Table 1), and
29% had undetectable PVL (<100 copies/ml). There was little
correlation between BMI and CD4%, or MUAC and CD4% among
HIV-2-infected individuals (r = 0.1 for both).Of the 37 stage-deﬁning conditions25 (grouping mucocutane-
ous manifestations), only nine were observed (Table 2). Some of
the conditions could not be diagnosed given limitations in
diagnostic facilities, and some conditions were excluded from
the algorithm (persistent fever because of the very high
background prevalence in HIV-negative subjects, and wasting
syndrome because its deﬁnition incorporates persistent fever). The
most commonly observed conditions among HIV-2-infected
individuals were peripheral generalized lymphadenopathy
(PGL), mucocutaneous manifestations, herpes zoster, pulmonary
tuberculosis (PTB), and severe weight loss.
A higher proportion of HIV-2-infected subjects (42%) had PGL
compared to HIV-negative subjects (18%, p < 0.001). Herpes zoster
was also observed in a higher proportion of HIV-2-infected
individuals (5%) than HIV-negative subjects (0.5%, p = 0.009). Six
percent of HIV-2-infected individuals had current or recent PTB
(diagnosed by medical history or clinically), compared to 3% of
HIV-negative individuals (p = 0.2).
Mucocutaneous manifestations and severe weight loss were
also common among HIV-negative subjects, and the proportions of
individuals with these conditions were only slightly lower than in
HIV-2-infected individuals.
The only stage 4-deﬁning condition observed in HIV-2-infected
individuals was esophageal candidiasis (one person).
3.3. Overall mortality
Participants were followed-up for a median of 6.2 years (range
0–7.4 years). Only 1% of participants were lost to follow-up. Seven
Table 1
Socio-demographic data, clinical measures, and laboratory markers of HIV-2-
infected and HIV-negative participants in a community cohort in Guinea-Bissau in
2003
Characteristics HIV-2, n (%)a
(n = 146)
HIV-negative,
n (%)a
(n = 197)
p-Value
Gender
Male 47 (32) 54 (27) 0.3
Female 99 (68) 143 (73)
Age (years)
15–29 4 (3) 23 (12) 0.01
30–44 35 (24) 50 (25)
45–59 47 (32) 47 (24)
60+ 60 (41) 77 (39)
Mean (SD) 55.9 (15) 52.8 (18) 0.1
Ethnic group
Manjako 146 (100) 189 (96) 0.01
Other 0 8 (4)
Zone
Central 115 (79) 154 (78) 0.9
Peripheral 31 (21) 43 (22)
Marital status
Single 22 (15) 35 (18) 0.3
Married 104 (71) 145 (74)
Divorced/widowed 20 (14) 17 (9)
BMI (kg/m2)b
<18.5 24 (17) 21 (11) 0.1
18.5 121 (83) 176 (89)
Median (IQR) 21.6 (19.7–24.4) 21.8 (19.6–24.3) 0.6
MUAC (mm)c
<230 W or <240 M 12 (8) 10 (5) 0.2
230 W or 240 M 134 (92) 187 (95)
Mean (SD) 278.7 (36.5) 282.3 (37.2) 0.4
WHO clinical staged
1 105 (72) 163 (83) 0.05
2 20 (14) 15 (8)
3/4 21 (14) 19 (10)
WHO performancee,f
1 57 (40) 92 (47) 0.4
2 57 (40) 69 (35)
3/4 30 (21) 34 (17)
CD4%g
<14 6 (4) 0 <0.001
14-28 41 (30) 5 (3)
>28 92 (66) 183 (97)
Median (IQR) 31 (26–38) 40 (36–46) <0.001
PVL (copies/ml)
<100 42 (29)
100–9999 74 (51)
10 000–99 999 23 (16)
100 000 7 (5)
Median (IQR) 1124 (50–6792)
BMI, body mass index; MUAC, mid-upper arm circumference; WHO, World Health
Organization; PVL, plasma viral load; SD, standard deviation; IQR, interquartile
range.
a Unless otherwise indicated.
b One missing value.
c Cut-offs: 230 mm for women (W) and 240 mm for men (M).
d WHO clinical stage assigned using an algorithm based on WHO staging criteria
for HIV infection (2006 revision25).
e Four missing values.
f WHO performance scale: 1 (asymptomatic, normal activity), 2 (symptomatic,
normal activity), 3 (bedridden <50% of the day), 4 (symptomatic and bedridden
>50% of the day).
g Sixteen missing values.
Table 2
Distribution of WHO stage-deﬁning conditions in a community cohort in Guinea-
Bissau in 2003a
Condition HIV-2, n (%)
(n = 146)
HIV-negative,
n (%)
(n = 197)
p-Value
Stage 1
PGL 61 (42) 36 (18) <0.001
Stage 2
Herpes zoster 7 (5) 1 (0.5) 0.009
Mucocutaneous manifestations 16 (11) 14 (7) 0.2
Stage 3
Severe weight loss 13 (9) 12 (6) 0.3
Oral candidiasis 2 (1) 0 0.1
Oral hairy leukoplakia 1 (0.7) 1 (0.5) 0.8
Anemia 1 (0.7) 0 0.2
Pulmonary tuberculosis 9 (6) 6 (3) 0.2
Stage 4
Esophageal candidiasis 1 (0.7) 0 0.2
WHO, World Health Organization; PGL, peripheral generalized lymphadenopathy.
a Conditions deﬁned according to WHO clinical staging criteria for HIV-
infection.25 The conditions are listed in Appendix A, with comments on how their
diagnosis was handled in the current study. Some individuals had two or more
conditions and appear in more than one stage in this table. Fifty-nine HIV-2-
infected and 135 HIV-negative individuals had none of the stage-deﬁning
conditions listed.
Table 3
Follow-up, mortality rates, and mortality hazard ratios for HIV-2-infected and HIV-
negative participants in a community cohort in Guinea-Bissau 2003–2010
HIV-2 (n = 146) HIV-negative
(n = 197)
Number (%) lost to follow-up 3 (2) –
Number (%) started ART 7 (5) –
Number (%) of deaths 44 (30) 28 (14)
Total follow-up (years) 775 1114
Mortality rate (95% CI) per 100 PYO 5.7 (4.2–7.6) 2.5 (1.7–3.6)
Crude MHR (95% CI) 2.1 (1.3–3.5) Ref.
Adjusted MHRa (95% CI) 1.9 (1.2–3.1) Ref.
ART, antiretroviral treatment; PYO, person-years of observation; MHR, mortality
hazard ratio; CI, conﬁdence interval.
a Adjusted for age and sex.
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individuals who started ART (26%, IQR 22–32%) was lower than that
for individuals who did not start ART (38%, IQR 31–44%) (p = 0.01). In
total, 72 subjects (21%) died: 44 (30%) HIV-2-infected individuals
and 28 (14%) HIV-negative individuals (Figure 1, Table 3).
HIV-2-infected persons experienced a mortality rate approxi-
mately double that of HIV-negative subjects (Table 3). The overall
mortality HR for HIV-2-infected subjects compared to theuninfected group, adjusted for age and sex, was 1.9 (95%
conﬁdence interval (CI) 1.2–3.1).
3.4. Clinical measures/socio-demographic factors and mortality
Gender was strongly associated with mortality. After adjust-
ment for age, CD4%, and PVL, females experienced 0.3 times the
mortality rate of males (95% CI 0.2–0.7). The HR was elevated
among the older age groups, with a strong overall effect of age on
mortality (p = 0.001 adjusted for sex, CD4%, and PVL) (Table 4).
An increasing trend in mortality HRs was observed with
decreasing CD4% in the crude analysis, and adjusted for age, sex,
and PVL (p = 0.04). Crude mortality rates also increased with
increasing category of PVL. There was evidence for an effect of PVL
on mortality after adjustment for age and sex (p < 0.001), and on
further adjustment for CD4% (p = 0.02).
HIV-2-infected individuals with BMI <18.5 kg/m2 had a higher
mortality rate than those with BMI 18.5 kg/m2 in the crude
analysis (HR 1.9, 95% CI 1.0–3.9, p = 0.08). Adjusted for age and sex,
the mortality HR was 1.8 (95% CI 0.9–3.8, p = 0.1), while the effect
was weaker on further adjustment for CD4% and PVL (HR 1.2, 95%
CI 0.5–3.0, p = 0.6). When other cut-offs of BMI were explored, the
strongest effect was observed among individuals with BMI <17 kg/
m2 (crude HR 3.6, 95% CI 1.4–9.5, p = 0.008; adjusted for age and
sex, HR 3.6, 95% CI 1.4–9.6, p = 0.02). There was weak evidence for
an association between MUAC and mortality in the univariate
Table 4
Crude mortality rates and crude and adjusted associations of socio-demographic and clinical factors with mortality, among HIV-2-infected individuals in a community cohort
in Guinea-Bissau, 2003–2010
Characteristic Deaths PYO Mortality rate
per 100 (95% CI)
Crude HR
(95% CI)
p-Valuea HR adjusted for
age and sex
(95% CI)
p-Valuea HR adjusted for
age, sex, CD4%,
and PVL (95% CI)
p-Valuea
Sex
Male 22 231.3 9.5 (6.3–14.4) 1 0.002 1 <0.001 1 0.003
Female 22 543.8 4.1 (2.7–6.1) 0.4 (0.2–0.7) 0.3 (0.2–0.6) 0.3 (0.2–0.7)
Age, yearsc
<40 1 109.0 0.9 (0.1–6.5) 1 0.004 1 <0.001 1 0.001
40–59 12 309.5 3.9 (2.2–6.8) 3.9 (0.5–30.3) 3.2 (0.4–24.5) 2.2 (0.3–17.2)
60 31 356.7 8.7 (6.1–12.4) 8.2 (1.1–60.1) 8.9 (1.2–65.2) 6.8 (0.9–50.7)
Marital status
Single 8 107.6 7.4 (3.7–14.9) 1 0.6 1 0.4 1 0.6
Married 28 560.3 5.0 (3.5–7.2) 0.6 (0.3–1.4) 0.5 (0.2–1.3) 0.6 (0.2–1.6)
Divorced/widowed 8 107.2 7.5 (3.7–14.9) 0.7 (0.3–1.9) 0.5 (0.2–1.8) 0.7 (0.2–3.1)
Zone
Central 34 602.9 5.6 (4.0–7.9) 1 0.7 1 0.7 1 0.3
Peripheral 10 172.3 5.8 (3.1–10.8) 1.1 (0.6–2.3) 1.1 (0.6–2.4) 1.5 (0.7–3.2)
BMI (kg/m2)
18.5 32 649.7 4.9 (3.5–7.0) 1 0.08 1 0.1 1 0.6
<18.5 11 120.8 9.1 (5.0–16.4) 1.9 (1.0–3.9) 1.8 (0.9–3.8) 1.2 (0.5–3.0)
MUAC (mm)d
230 W or 240 M 38 721.7 5.3 (3.8–7.2) 1 0.1 1 0.3 1 0.5
<230 W or <240 M 6 53.5 11.2 (5.0–25.0) 2.2 (0.9–5.3) 1.60 (0.7–3.9) 1.5 (0.6–4.0)
WHO clinical stage
1 29 560.7 5.2 (3.6–7.4) 1 0.6 1 0.9 1 0.5
2 7 106.8 6.6 (3.1–13.8) 1.2 (0.5–2.7) 1.2 (0.5–2.8) 1.1 (0.5–2.9)
3/4 8 107.6 7.4 (3.7–14.9) 1.5 (0.7–3.2) 1.2 (0.5–2.7) 0.6 (0.2–1.6)
WHO performance
1 11 311.4 3.5 (2.0–6.4) 1 0.2 1 0.6 1 0.5
2 22 284.6 7.7 (5.1–11.7) 1.9 (0.9–3.9) 1.4 (0.7–2.9) 1.6 (0.7–3.4)
3/4 11 167.7 6.6 (3.6–11.8) 1.7 (0.7–3.9) 1.0 (0.4–2.4) 1.2 (0.5–3.3)
CD4%
>28 17 506.0 3.4 (2.1–5.4) 1 0.001 1 0.001 1 0.08
14–28 19 209.6 9.1 (5.8–14.2) 2.5 (1.3–5.0) 2.0 (1.0–3.9) 1.6 (0.7–3.4) 0.04b
<14 5 23.9 20.9 (8.7–50.2) 7.9 (2.9–21.8) 9.7 (3.4–27.4) 4.8 (1.3–17.5)
PVL (copies/ml)
<10 000 25 638.9 3.9 (2.6–5.8) 1 <0.001 1 <0.001 1 0.07
10 000–99 999 14 112.2 12.5 (7.4–21.1) 3.0 (1.6–5.9) 3.3 (1.7– 6.5) 1.9 (0.8–4.5) 0.02b
100 000 5 24.1 20.8 (8.6–49.9) 7.5 (2.8–20.3) 4.8 (1.7–13.2) 3.8 (1.3–11.3)
PYO, person-years observation; CI, conﬁdence interval; HR, hazard ratio; PVL, plasma viral load; BMI, body mass index; MUAC, mid-upper arm circumference; WHO, World
Health Organization.
a Likelihood ratio test (LRT).
b LRT for trend.
c Age analyzed as a time-varying variable.
d Cut-offs: 230 mm for women (W) and 240 mm for men (M).
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association in the adjusted analyses.
The crude mortality rate increased with each (higher) WHO
stage, though the association was weak (p = 0.6). Crude mortality
rates were also higher in categories 2 and 3/4 of the WHO
performance scale compared to category 1, but with no evidence of
a trend.
4. Discussion
4.1. Key ﬁndings
This is the ﬁrst study to analyze clinical predictors of mortality
in HIV-2-infected individuals in a community setting, with
excellent follow-up. We did not identify any clinical measures
that were strong predictors of mortality: there was only weak
statistical evidence for an association between BMI or MUAC and
mortality, and no statistical evidence to support an association
between WHO stage or performance scale and mortality, once
adjusted for age and sex. These ﬁndings suggest that, in a
community-based setting, these clinical measures are less reliable
than CD4 count or viral load for guiding treatment decisions in
HIV-2-infected patients.Our ﬁndings also demonstrate that a high proportion of HIV-2-
infected individuals in this cohort, many of whom were infected at
least since 1989 or 1997, did not show clinical signs of disease
progression: a majority were in WHO clinical stage 1 and had
normal BMI or MUAC. These clinical ﬁndings support the
observations of long-term low PVL observed among individuals
in this cohort.12 We observed a mortality rate in HIV-2-infected
individuals approximately two times that of HIV-negative
individuals, which is consistent with earlier reports from this
cohort5,12 and other study sites.3,26
CD4% and PVL were strong predictors of mortality among HIV-
2-infected subjects in this analysis, consistent with the results of
previous studies,2,5,11,12 and showing that the failure to ﬁnd an
association with clinical predictors was not simply due to lack of
power.
4.2. Clinical predictors
BMI was not strongly associated with mortality, in contrast to a
clinic-based study in The Gambia, which reported that BMI was a
strong predictor of mortality in patients with HIV-2 infection.14
The Gambian study was conducted among patients with more
advanced disease who attended a clinic, whereas individuals in
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that while BMI may be a useful alternative to CD4 count or PVL for
HIV-2 patient management in a clinic-based setting, it may be less
important in a community-based setting. Lack of power may also
explain the failure to detect an effect, especially given the small
number of individuals and events below the cut-offs deﬁned. The
cut-off chosen reﬂects published guidelines for the identiﬁcation of
malnutrition. We also explored a range of alternative cut-offs
between 17 kg/m2 and 21 kg/m2, and found a stronger effect
among patients with BMI <17 kg/m2; however less than 5% of HIV-
2-infected subjects were in this category.
MUAC may serve as another inexpensive and easily measured
proxy for nutritional status,24but we found only weak evidence for an
association with mortality among HIV-2-infected individuals in this
cohort. MUAC <200 mm was associated with an increased risk of
death in an urban cohort of HIV-positive (HIV-1, HIV-2, and dual) and
HIV-negative TB patients in Guinea-Bissau,27however the majority of
participants were HIV-negative, and results among advanced HIV-
positive patients with TB are probably not generalizable.
WHO clinical stage was not associated with mortality in HIV-2-
infected individuals in this study. This result may suggest that
clinical stage is not as useful in evaluating the prognosis of HIV-2-
infected as HIV-1-infected patients. However, a signiﬁcant
association between WHO stage and mortality among HIV-2-
infected individuals was found in another study from a Gambian
clinic.2 Limitations to the staging algorithm used in the current
analysis may explain the difference between the studies. The
algorithm was based on only a subset of the stage-deﬁning criteria.
Identiﬁcation of most stage 4-deﬁning conditions requires
diagnostic procedures that were not available in this setting,
although this is the reality in many rural clinics. Only one stage 4-
deﬁning condition was identiﬁed, though more may have been
present that could not be diagnosed. As a result, there may be more
individuals in stage 4 who were categorized in earlier stages,
diluting the predictive effect. Small numbers of individuals
identiﬁed in stage 3/4 may have reduced the power. Kaposi’s
sarcoma was not identiﬁed in HIV-2-infected subjects in this
cohort, a result that concurs with other studies that have reported
that this condition is relatively rare in HIV-2- compared to HIV-1-
infected individuals.28,29
We found no evidence for an association between WHO
performance scale and HIV-2 infection in this study, nor did we
ﬁnd an association between the performance scale and mortality
among HIV-2-infected subjects. WHO performance scale has not
previously been investigated in its own right as a potential
predictor of mortality in HIV-infection, though a similar perfor-
mance scale, the Karnofsky score, was an indicator of mortality in
HIV-1- and HIV-2-infected patients in Gambian clinics.2,20
4.3. Limitations
When this cohort was formed, HIV-infected and HIV-negative
individuals were matched on age, but HIV-2-infected individuals
were older than HIV-negative subjects in our analysis. This is
because HIV-1-infected and HIV dual-infected individuals were
excluded from this analysis, and they are younger than HIV-2-
infected individuals.
Non-differential misclassiﬁcation of BMI, MUAC, and WHO
performance scale or stage may have diluted the effects observed
for each of these exposures. Assessment may have differed
between the three study physicians, though this was unlikely to
have been systematically biased given the assessments were made
without knowledge of the outcome. Such limitations would,
however, be the reality in clinical or public health practice.
HIV status at baseline was used in the analysis. Seroconversions
to HIV-1/2 dual infection among HIV-2-infected individuals duringthe follow-up period could have biased the associations for each
clinical measure with mortality. Information on seroconversions
was only available from one serological survey in 2006, when only
60% of the cohort was re-bled: only three HIV-2-infected
individuals had seroconverted to HIV-1/2 dual infection. Other
seroconversions could have occurred after 2006, though it is
unlikely that these would have affected our conclusions. That the
exact dates of seroconversion are unknown for individuals in this
cohort is a limitation, as age at seroconversion strongly inﬂuences
survival in HIV-1 infection.30
Censoring subjects on ART may have underestimated the
mortality rate in the HIV-2-infected group if these individuals were
closer to death than subjects who were not censored. Individuals
who started ART had lower CD4% than those who did not, however
as only seven individuals had started ART this is unlikely to have
introduced a considerable bias and affected our conclusions. It is
unlikely that any participants were taking and adhering to ART
obtained from outside the study site, as the only other health
centers administering ART are located at considerable distances
from Caio – in Bissau, the capital, or Senegal – and ART was only
introduced in Bissau in 2006.
We did not analyze cause of death, and whether HIV-infected
individuals died from HIV-related conditions is unknown. This
may be particularly useful to determine in this cohort, where
background mortality is high and many participants were
relatively old. Cause of death was investigated previously in
this cohort using a verbal autopsy:31 AIDS-related deaths were
observed among HIV-1, HIV-2, and HIV-1/2 dually infected
individuals and were least frequent among HIV-2-infected
people.
Clinical measures were only analyzed at baseline in 2003, as
clinical data at subsequent time-points were limited. However,
repeated measurements and changes in clinical status over time
may still be useful in predicting mortality.
5. Conclusions
In this community-based setting, none of four examined clinical
measures at baseline (BMI, MUAC, WHO stage, and WHO
performance scale) were useful alternatives to CD4 or PVL in
predicting mortality among HIV-2-infected individuals. Where
possible, laboratory markers should be used to guide the
management of HIV-2-infected individuals in the community-
based setting.
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Appendix A
List of conditions used in the WHO clinical staging criteria for
HIV infection,25 with comments of how their diagnosis was
handled in the current study.
A.J. Gourlay et al. / International Journal of Infectious Diseases 16 (2012) e337–e343 e343A.1. Stage 1 conditions
Peripheral generalized lymphadenopathy (PGL): lymph nodes
present at two or more sites excluding inguinal; clinical diagnosis.
A.2. Stage 2 conditions
 Herpes zoster: current or in last 5 years.
 Mucocutaneous manifestations: fungal nail infection, dermatitis,
or papular rash; clinical diagnosis.
 Moderate weight loss 5–10% body weight: could not be deﬁned.
 Recurrent upper respiratory tract infections, angular cheilitis,
recurrent oral ulceration: not observed among HIV-2-infected
individuals in this study.
A.3. Stage 3 conditions
 Severe weight loss: 10% weight loss (physician assessment) and
BMI <18.5 kg/m2.
 Oral candidiasis: clinical diagnosis.
 Oral hairy leukoplakia: clinical diagnosis.
 Anemia: hemoglobin <8 g/dl.
 Pulmonary tuberculosis: current or recent; clinical diagnosis or
medical history.
 Chronic diarrhea >1 month: duration could not be deﬁned.
 Unexplained persistent fever: patient recall of fever or night
sweats >1 month, excluding cases where malarial parasites were
detected. Excluded from the clinical staging algorithm due to the
high background prevalence observed in HIV-negative subjects
(31%) (38% in HIV-2-infected subjects).
 Severe bacterial infection, acute necrotizing ulcerative gingivitis/
periodontitis: not observed among HIV-2-infected individuals in
this study.
A.4. Stage 4 conditions
 Esophageal candidiasis: oral candidiasis plus pain on swallowing.
 HIV wasting syndrome: excluded from the clinical staging
algorithm as persistent fever is used in the deﬁnition of wasting.
 Kaposi’s sarcoma, Pneumocystis pneumonia, recurrent bacterial
pneumonia, extrapulmonary tuberculosis, cytomegalovirus dis-
ease, central nervous system toxoplasmosis, HIV encephalopa-
thy, extrapulmonary cryptococcosis: not observed among HIV-2-
infected individuals in this study.
 Chronic herpes simplex >1 month: duration could not be
deﬁned.
 Disseminated non-tuberculous mycobacteria infection, progres-
sive multifocal leukoencephalopathy, chronic cryptosporidiosis,
chronic isosporiasis, disseminated mycosis, recurrent non-typhoid
Salmonella bacteremia, lymphoma, invasive cervical carcinoma,
atypical disseminated leishmaniasis, HIV-associated nephropathy/
cardiomyopathy: no facilities to diagnose these conditions.
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